Quadrant Capital Group LLC Chemo Centryx, Inc. Transaction History

Quadrant Capital Group LLC

$1.42 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	BUY	$22.17 - $51.8 $88 - $207	4 Added 0.96%	422 $22,000
Q3 2021 Nov 12, 2021	BUY	$13.18 - $19.83 $5,298 - $7,971	402 Added 2512.5%	418 $7,000
Q2 2021 Aug 09, 2021	BUY	$9.59 - $50.88 $124 - $661	13 Added 433.33%	16 $0
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $141 - $195	-3 Reduced 50.0%	3 $0
Q3 2020 Nov 13, 2020	SELL	$46.35 - $61.69 $370 - $493	-8 Reduced 57.14%	6 $0
Q2 2020 Aug 13, 2020	BUY	$38.58 - $65.07 $540 - $910	14 New	14 $1,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.